Cite
HARVARD Citation
Johnson, T. et al. (n.d.). 101P Results of the NLG2105 phase I trial using the IDO pathway inhibitor indoximod, in combination with radiation and chemotherapy, for children with newly diagnosed DIPG. Annals of oncology. p. . [Online].